Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma

Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging

(2009) Jennifer L. Clarke et al.   Current Neurology and Neuroscience Reports

Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression

(2009) Elizabeth R. Gerstner et al.   JOURNAL OF NEURO-ONCOLOGY

Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target

(2009) Randy L. Jensen   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

The parametric response map is an imaging biomarker for early cancer treatment outcome

(2009) Craig J Galbán et al.   NATURE MEDICINE

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging

(2008) Meng Law et al.   RADIOLOGY

Response criteria for glioma

(2008) A Gregory Sorensen et al.   Nature clinical practice. Oncology